Advertisement

Antiviral Drugs for the Therapeutics of SFTS

  • Hideki TaniEmail author
  • Masayuki Saijo
Chapter

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) virus (SFTSV) is the causative agent of SFTS. Despite the medical importance of this disease, there are currently neither vaccines nor effective therapeutics for SFTS. Ribavirin has been an effective antiviral drug against several RNA virus infections. Favipiravir, which is a pyrazine derivative, has also shown broad antiviral activity against various RNA viruses. In this chapter, characteristics of ribavirin and favipiravir in viral infection and their antiviral effects in the treatment of SFTSV infections in vivo are described.

Keywords

Antivirals Ribavirin Favipiravir T-705 SFTS 

References

  1. Baba M, Toyama M, Sakakibara N, Okamoto M, Arima N, Saijo M (2017) Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors. Antivir Chem Chemother 25:83–89CrossRefGoogle Scholar
  2. Bai CQ, Mu JS, Kargbo D, Song YB, Niu WK, Nie WM, Kanu A, Liu WW, Wang YP, Dafae F, Yan T, Hu Y, Deng YQ, Lu HJ, Yang F, Zhang XG, Sun Y, Cao YX, Su HX, Sun Y, Liu WS, Wang CY, Qian J, Liu L, Wang H, Tong YG, Liu ZY, Chen YS, Wang HQ, Kargbo B, Gao GF, Jiang JF (2016) Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014. Clin Infect Dis 63:1288–1294CrossRefGoogle Scholar
  3. Bougie I, Bisaillon M (2004) The broad spectrum antiviral nucleoside ribavirin as a substrate for a viral RNA capping enzyme. J Biol Chem 279:22124–22130CrossRefGoogle Scholar
  4. Carrillo-Bustamante P, Nguyen THT, Oestereich L, Gunther S, Guedj J, Graw F (2017) Determining Ribavirin’s mechanism of action against Lassa virus infection. Sci Rep 7:11693CrossRefGoogle Scholar
  5. Chen XP, Cong ML, Li MH, Kang YJ, Feng YM, Plyusnin A, Xu J, Zhang YZ (2012) Infection and pathogenesis of Huaiyangshan virus (a novel tick-borne bunyavirus) in laboratory rodents. J Gen Virol 93:1288–1293CrossRefGoogle Scholar
  6. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, Andino R, Cameron CE (2000) The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 6:1375–1379CrossRefGoogle Scholar
  7. Ferm VH, Willhite C, Kilham L (1978) Teratogenic effects of ribavirin on hamster and rat embryos. Teratology 17:93–101CrossRefGoogle Scholar
  8. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, Nomura N, Egawa H, Minami S, Watanabe Y, Narita H, Shiraki K (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977–981CrossRefGoogle Scholar
  9. Gowen BB, Westover JB, Sefing EJ, Van Wettere AJ, Bailey KW, Wandersee L, Komeno T, Furuta Y (2017) Enhanced protection against experimental Junin virus infection through the use of a modified favipiravir loading dose strategy. Antivir Res 145:131–135CrossRefGoogle Scholar
  10. Kamiyama N, Soma R, Hidano S, Watanabe K, Umekita H, Fukuda C, Noguchi K, Gendo Y, Ozaki T, Sonoda A, Sachi N, Runtuwene LR, Miura Y, Matsubara E, Tajima S, Takasaki T, Eshita Y, Kobayashi T (2017) Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice. Antivir Res 146:1–11CrossRefGoogle Scholar
  11. Kochhar DM, Penner JD, Knudsen TB (1980) Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52:99–112CrossRefGoogle Scholar
  12. Liu Y, Wu B, Paessler S, Walker DH, Tesh RB, Yu XJ (2014) The pathogenesis of severe fever with thrombocytopenia syndrome virus infection in alpha/beta interferon knockout mice: insights into the pathologic mechanisms of a new viral hemorrhagic fever. J Virol 88:1781–1786CrossRefGoogle Scholar
  13. Lu QB, Zhang SY, Cui N, Hu JG, Fan YD, Guo CT, Qin SL, Yang ZD, Wang LY, Wang HY, Zhang XA, Liu W, Cao WC (2015) Common adverse events associated with ribavirin therapy for severe fever with thrombocytopenia syndrome. Antivir Res 119:19–22CrossRefGoogle Scholar
  14. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314:20–26CrossRefGoogle Scholar
  15. McKee KT Jr, Huggins JW, Trahan CJ, Mahlandt BG (1988) Ribavirin prophylaxis and therapy for experimental argentine hemorrhagic fever. Antimicrob Agents Chemother 32:1304–1309CrossRefGoogle Scholar
  16. Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, Wurr S, Emmerich P, de Lamballerie X, Olschlager S, Gunther S (2014a) Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS Negl Trop Dis 8:e2804CrossRefGoogle Scholar
  17. Oestereich L, Ludtke A, Wurr S, Rieger T, Munoz-Fontela C, Gunther S (2014b) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antivir Res 105:17–21CrossRefGoogle Scholar
  18. Oestereich L, Rieger T, Ludtke A, Ruibal P, Wurr S, Pallasch E, Bockholt S, Krasemann S, Munoz-Fontela C, Gunther S (2016) Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213:934–938CrossRefGoogle Scholar
  19. Oh WS, Heo ST, Kim SH, Choi WJ, Han MG, Kim JY (2014) Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopenia syndrome. Int J Infect Dis 18:84–86CrossRefGoogle Scholar
  20. Park I, Kim HI, Kwon KT (2017) Two treatment cases of severe fever and thrombocytopenia syndrome with oral ribavirin and plasma exchange. Infect Chemother 49:72–77CrossRefGoogle Scholar
  21. Rattanaburee T, Junking M, Panya A, Sawasdee N, Songprakhon P, Suttitheptumrong A, Limjindaporn T, Haegeman G, Yenchitsomanus PT (2015) Inhibition of dengue virus production and cytokine/chemokine expression by ribavirin and compound A. Antivir Res 124:83–92CrossRefGoogle Scholar
  22. Scharton D, Bailey KW, Vest Z, Westover JB, Kumaki Y, Van Wettere A, Furuta Y, Gowen BB (2014) Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antivir Res 104:84–92CrossRefGoogle Scholar
  23. Shimada S, Posadas-Herrera G, Aoki K, Morita K, Hayasaka D (2015) Therapeutic effect of post-exposure treatment with antiserum on severe fever with thrombocytopenia syndrome (SFTS) in a mouse model of SFTS virus infection. Virology 482:19–27CrossRefGoogle Scholar
  24. Shimojima M, Fukushi S, Tani H, Yoshikawa T, Fukuma A, Taniguchi S, Suda Y, Maeda K, Takahashi T, Morikawa S, Saijo M (2014) Effects of ribavirin on severe fever with thrombocytopenia syndrome virus in vitro. Jpn J Infect Dis 67:423–427CrossRefGoogle Scholar
  25. Shimojima M, Fukushi S, Tani H, Taniguchi S, Fukuma A, Saijo M (2015) Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection. Virol J 12:181CrossRefGoogle Scholar
  26. Sissoko D, Laouenan C, Folkesson E, M’Lebing AB, Beavogui AH, Baize S, Camara AM, Maes P, Shepherd S, Danel C, Carazo S, Conde MN, Gala JL, Colin G, Savini H, Bore JA, Le Marcis F, Koundouno FR, Petitjean F, Lamah MC, Diederich S, Tounkara A, Poelart G, Berbain E, Dindart JM, Duraffour S, Lefevre A, Leno T, Peyrouset O, Irenge L, Bangoura N, Palich R, Hinzmann J, Kraus A, Barry TS, Berette S, Bongono A, Camara MS, Chanfreau Munoz V, Doumbouya L, Souley H, Kighoma PM, Koundouno FR, Rene L, Loua CM, Massala V, Moumouni K, Provost C, Samake N, Sekou C et al (2016) Experimental treatment with favipiravir for ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 13:e1001967CrossRefGoogle Scholar
  27. Smither SJ, Eastaugh LS, Steward JA, Nelson M, Lenk RP, Lever MS (2014) Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antivir Res 104:153–155CrossRefGoogle Scholar
  28. Tam RC, Lau JY, Hong Z (2001) Mechanisms of action of ribavirin in antiviral therapies. Antivir Chem Chemother 12:261–272CrossRefGoogle Scholar
  29. Tani H, Fukuma A, Fukushi S, Taniguchi S, Yoshikawa T, Iwata-Yoshikawa N, Sato Y, Suzuki T, Nagata N, Hasegawa H, Kawai Y, Uda A, Morikawa S, Shimojima M, Watanabe H, Saijo M (2016) Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere 1:e00061-15Google Scholar
  30. Westover JB, Sefing EJ, Bailey KW, Van Wettere AJ, Jung KH, Dagley A, Wandersee L, Downs B, Smee DF, Furuta Y, Bray M, Gowen BB (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antivir Res 126:62–68CrossRefGoogle Scholar
  31. Yoshikawa T, Fukushi S, Tani H, Fukuma A, Taniguchi S, Toda S, Shimazu Y, Yano K, Morimitsu T, Ando K, Yoshikawa A, Kan M, Kato N, Motoya T, Kuzuguchi T, Nishino Y, Osako H, Yumisashi T, Kida K, Suzuki F, Takimoto H, Kitamoto H, Maeda K, Takahashi T, Yamagishi T, Oishi K, Morikawa S, Saijo M, Shimojima M (2014) Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load. J Clin Microbiol 52:3325–3333CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Department of Virology, Graduate School of Medicine and Pharmaceutical SciencesUniversity of ToyamaToyamaJapan
  2. 2.Department of Virology 1National Institute of Infectious DiseasesTokyoJapan

Personalised recommendations